Skip to ContentSkip to Navigation
Over ons Praktische zaken Waar vindt u ons J.R. (Jacobien) Hilberink

Publicaties

A 4-gene prognostic index for enhancing acute myeloid leukaemia survival prediction

Decitabine in the treatment of acute myeloid leukemia: clinical aspects and immunological opportunities

Thiostrepton induces cell death of acute myeloid leukemia blasts and the associated macrophage population

Age and sex associate with outcome in older AML and high risk MDS patients treated with 10-day decitabine

M2 macrophages drive leukemic transformation by imposing resistance to phagocytosis and improving mitochondrial metabolism

The PIP4K2 inhibitor THZ-P1-2 exhibits antileukemia activity by disruption of mitochondrial homeostasis and autophagy

Low relapse risk in poor risk AML after conditioning with 10-day decitabine, fludarabine and 2 Gray TBI prior to allogeneic hematopoietic cell transplantation

Pretransplantation MRD in Older Patients With AML After Treatment With Decitabine or Conventional Chemotherapy

Secondary cytogenetic abnormalities in core-binding factor AML harboring inv(16) vs t(8;21)

Not type of induction therapy but consolidation with allogeneic hematopoietic cell transplantation determines outcome in older AML patients: A single center experience of 355 consecutive patients